RxDoctor Payments Data

Craig Smith, MD

Ophthalmology · Dallas, TXNPI 1821083379

Payments from drug & device makers

$554in general payments, 2019–2025

Across 16 payments — averaging $34.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$141
  • Eyevance Pharmaceuticals LLC$124
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$69
  • Bausch & Lomb Americas Inc.$64
  • Novartis$47
  • AbbVie$24
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$51793%
  • Gifts$377%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$554 in reported general payments places this provider in the 25th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$149,185
Medicare patients
627
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod39$16,983
RestasisCyclosporine13$13,121
XiidraLifitegrast18$12,730
LumiganBimatoprost11$7,058
Cyclosporine14$7,000
SimbrinzaBrinzolamide/Brimonidine Tart15$6,617
Travoprost38$5,031
Tobramycin-DexamethasoneTobramycin/Dexamethasone88$4,518
Prednisolone Acetate87$2,462
Flurbiprofen Sodium71$2,050
Brimonidine Tartrate15$1,252
Ciprofloxacin Hcl77$1,026
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate74$682
Latanoprost75$635
ErythromycinErythromycin Base32$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$64$29,71357 claims
AbbVieRestasis, Lumigan$24$20,17924 claims
AlconSimbrinza$21$6,61715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →